Business Model Breakdown
How MiMedx Group Inc Makes Money
MDXG
Market Cap
$575M
Annual Revenue
$393M
Profit Margin
11.6%
Employees
837
The Short Version
MiMedx Group Inc. develops, manufactures, and markets innovative regenerative and therapeutic biologics products derived from human amniotic tissue. These products, such as EpiFix and AmnioFix, are primarily used in advanced wound care to treat chronic and acute wounds, and increasingly in surgical and orthopedic applications to aid healing and tissue regeneration. The company generates revenue by selling these proprietary biologics directly to hospitals, wound care centers, surgical facilities, and physicians through its dedicated sales force.
Where the Revenue Comes From
Sale of biologics products for wound care (~67% of Q4 2025 total revenue)
Sale of biologics products for surgical and orthopedic applications (~33% of Q4 2025 total revenue)
Who buys: Hospitals, surgical centers, wound care clinics, and individual physicians/surgeons.
Why It Works (Competitive Advantages)
- ✔Proprietary biologics platform based on human amniotic tissue
- ✔Accumulated clinical evidence and established product efficacy
- ✔Differentiated product offerings in niche regenerative medicine
Economic Moat: Narrow (Intangible Assets/IP, Switching Costs)
What Our Analysis Says
DVR Score as of April 14, 2026
Score Change Explanation: The significant upward revision in score from 5.8 to 7.9 is primarily driven by the robust Q4 and full year 2025 earnings report. The company demonstrated strong financial progress with Q4 net sales growing 27% year-over-year and, crucially, reported positive GAAP net income of $15 million and adjusted EPS of $0.14. This tangible return to profitability and accelerated revenue growth confirms the successful execution of its strategic pivot and turnaround, establishing a more credible path to market leadership and de-risking the investment thesis considerably compared to the previous analysis. MiMedx is demonstrating strong execution of its turnaround, with Q4 2025 results showing robust 27% YoY revenue growth and a return to profitability (GAAP net income $15M). This validates its strategic pivot into higher-growth orthopedic segments while stabilizing core wound care. The proprietary biologics platform provides a competitive advantage. While specific balance sheet and cash flow metrics were not provided in the current intelligence, the return to profitability implies improved financial health. The 10x potential remains high-risk but is bolstered by sustained operational momentum and positive financial inflection. Lack of detailed analyst or insider sentiment data prevents a higher score.